• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Vimian’s Interim Report for the first quarter of 2026

Vimian Group
Download the release

Positive start to the year

  • Revenue increased by 8 per cent to EUR 116.0m (107.5) with organic growth of 9 per cent
  • Adjusted EBITA increased 3 per cent to EUR 29.2m (28.3) corresponding to a margin of 25.2 per cent (26.3)
  • Operating profit (EBIT) of EUR 21.2m (15.6)
  • Profit for the period of EUR 10.1m (4.7) and earnings per share before and after dilution EUR 0.02 (0.01)
  • Cash flow from operating activities of EUR 23.0m (17.1)

“Vimian is off to a good start to 2026 with positive momentum in our Group. We report 8 per cent total growth to EUR 116 million in revenues, with strong organic growth of 9 per cent. Three out of four segments deliver double-digit organic growth, ahead of the global animal health market, says Alireza Tajbakhsh, CEO Vimian Group, and continues:

“Adjusted EBITA grew 3 per cent to EUR 29.2 million at a margin of 25.2 per cent (26.3), impacted by our investments to drive growth in MedTech orthopedics and new market entries within Veterinary Services. We continued to deliver strong operational cash generation and completed two acquisitions in the quarter, adding in total EUR 10 million in annual revenues to the Group.”

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q1-report-2026/dial-in

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q1-report-2026

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.

For further information, please contact:


Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 73 626 88 86

About Vimian


Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches veterinary clinics and laboratories in over 80 markets, has 1,300 employees and annual revenues of approximately EUR 425 million. For more information, please visit: www.vimian.com.

This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-29 07:45 CEST.

Attachments


Vimian Interim Report Q126
Vimian Q126 Presentation